高级检索
当前位置: 首页 > 详情页

Psyllium seed husk regulates the gut microbiota and improves mucosal barrier injury in the colon to attenuate renal injury in 5/6 nephrectomy rats

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Guangzhou Univ Chinese Med, Clin Coll 2, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China [2]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Nephrol Dept, Guangzhou, Peoples R China
出处:
ISSN:

关键词: Chronic kidney disease psyllium seed husk gut microbiota colon mucosal barrier renal-protective

摘要:
Chronic kidney disease (CKD) can cause gut microbiota dysbiosis and thus impair intestinal barrier function. Disruption of intestinal homeostasis facilitates the production of enterogenic toxins, which exacerbate CKD-induced uremic toxicity and inflammation. Dietary fiber, by targeting the gut-kidney axis, could be used for CKD treatment. Psyllium seed husk (PSH) extracted from the seeds of Plantago ovata contains highly branched, gel-forming arabinoxylan. Positive effects of PSH on host physiology have been demonstrated but whether it also acts on the microbial ecosystem in CKD patients is unknown. In this study, the effects of dietary PSH on the gut microbiota, intestinal barrier function, systemic inflammation, uremic toxins, and renal injury were investigated in 5/6 nephrectomy (5/6Nx) CKD rats. Blood, feces, and kidney and colon tissues were collected from PSH-treated and control rats and subjected to biochemical and histological analyses, enzyme-linked immunosorbent assays, and 16SrRNA sequencing. PSH supplementation reduced serum creatinine and blood urea nitrogen levels, and attenuated renal tubular interstitial injury, in 5/6Nx rats. 16SrRNA sequencing showed that PSH improved the gut microbiota and intestinal barrier function in addition to down-regulating serum interleukin (IL)-1, IL-6, and indoxyl sulfate levels. Together, these results demonstrate the potential of PSH supplementation for treating CKD, including by improving intestinal microecology, reducing uremic toxin levels and systemic inflammation, and delaying disease progression.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 医学
小类 | 3 区 泌尿学与肾脏学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 泌尿学与肾脏学
JCR分区:
出版当年[2021]版:
Q2 UROLOGY & NEPHROLOGY
最新[2023]版:
Q1 UROLOGY & NEPHROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Guangzhou Univ Chinese Med, Clin Coll 2, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Guangzhou Univ Chinese Med, Clin Coll 2, State Key Lab Dampness Syndrome Chinese Med, Guangzhou, Peoples R China [2]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Nephrol Dept, Guangzhou, Peoples R China [*1]State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China [*2]Nephrology Department, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号